Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

Raltegravir (RAL) is a novel and potent human immunodeficiency virus type 1 integrase inhibitor that is predominantly metabolized via glucuronidation. The protease inhibitor combination tipranavir (TPV) at 500 mg and ritonavir (RTV) at 200 mg (TPV-RTV) has inhibitory and inductive effects on metabol...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hanley, William D., Wenning, Larissa A., Moreau, Allison, Kost, James T., Mangin, Eric, Shamp, Trisha, Stone, Julie A., Gottesdiener, Keith M., Wagner, John A., Iwamoto, Marian
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology (ASM) 2009
Schlagworte:
Pharmacology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2704640/
https://ncbi.nlm.nih.gov/pubmed/19398643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01486-08
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge